Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Operating Leases (2019 - 2025)

Denali Therapeutics (DNLI) has disclosed Operating Leases for 7 consecutive years, with $27.2 million as the latest value for Q4 2025.

  • Quarterly Operating Leases fell 25.8% to $27.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $27.2 million through Dec 2025, down 25.8% year-over-year, with the annual reading at $27.2 million for FY2025, 25.8% down from the prior year.
  • Operating Leases for Q4 2025 was $27.2 million at Denali Therapeutics, down from $38.8 million in the prior quarter.
  • The five-year high for Operating Leases was $62.9 million in Q1 2021, with the low at $27.2 million in Q4 2025.
  • Average Operating Leases over 5 years is $49.1 million, with a median of $50.9 million recorded in 2022.
  • The sharpest move saw Operating Leases grew 0.0% in 2024, then crashed 34.14% in 2025.
  • Over 5 years, Operating Leases stood at $58.6 million in 2021, then dropped by 9.43% to $53.0 million in 2022, then decreased by 15.18% to $45.0 million in 2023, then fell by 18.47% to $36.7 million in 2024, then decreased by 25.8% to $27.2 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $27.2 million, $38.8 million, and $32.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.